Hepatocellular Carcinoma Resectable Clinical Trial
Official title:
Differential Hypermethylation Status of the VTRNA2-1 Promoter in Hepatocellular Carcinoma as an Independent Factor After Partial Hepatectomy
The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.
This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06157060 -
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
|
||
| Not yet recruiting |
NCT04850040 -
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
|
Phase 2 | |
| Completed |
NCT06294808 -
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
|
||
| Recruiting |
NCT06003673 -
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
|
Phase 4 | |
| Recruiting |
NCT05766605 -
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
|
Phase 3 |